Cancer Res Treat.  2021 Apr;53(2):528-540. 10.4143/crt.2020.833.

Comparison of the Prognostic Value of Platelet-Related Indices in Biliary Tract Cancer Undergoing Surgical Resection

• Sun L
• Wei Y
• Chen Y
• Hu W
• Ji X
• Xu H
• Du S
• Zhao H
• Lu X
• Sang X
• Zhong S
• Yang H
• Mao Y

• KMID: 2514933
• DOI: http://doi.org/10.4143/crt.2020.833

Abstract

Purpose
Platelet-related indices, including mean platelet volume (MPV) and plateletocrit (PCT), have been reported as new prognostic factors of overall survival (OS) in many cancers, but not yet in biliary tract cancer (BTC). We intended to assess these indices in predicting OS in BTC patients with the aim to build a new prognostic model for patients with BTC after surgical resection.
Materials and Methods
Survival analysis and time receiver operating characteristic analysis were applied to screen the platelet indices. Univariate and multivariate Cox analyses were used to identify independent prognostic factors and develop a new prognostic model. Harrell’s C-statistics, calibration curves, and decisive curve analysis were used to assess the model.
Results
MPV and platelet distribution width (PDW)/PCT showed the best prognostic accuracy among the platelet indices. In multivariable analysis, factors predictive of poor OS were presence of nodal involvement, Non-radical surgery, poor tumor differentiation, carbohydrate antigen 19-9 > 100 U/mL, MPV > 8.1 fl, and PDW/PCT > 190. The new model was found to be superior to the TNM staging system and our new staging system showed higher discriminative power.
Conclusion
MPV and PDW/PCT have high prognostic value in BTC patients, and the novel staging system based on these two indices showed good discrimination and accuracy compared with the American Joint Committee on Cancer 7th TNM staging system.

Keyword

Biliary tract neoplasms; Platelet; Prognosis; Mean platelet volume; Platelet distribution width; plateletocrit

Figure

• 

  Fig. 1 Time-AUC curves of the platelet indices for overall survival prediction. AUC, area under curve; MPV, mean platelet volume; PCT, plateletocrit; PDW, platelet distribution width; PLR, platelet-to-lymphocyte ratio; PLT, platelet count; Time-AUC, areas under time-dependent ROC curves.

• 

  Fig. 2 Nomogram for predicting the 1-, 3-, 5-year, and median survival in patients with biliary tract cancer lines are drawn upward to determine the points for each variable. Total points represent the sum of points corresponding to each variable. Another line is drawn downward to determine the survival probability for total points. CA19-9, carbohydrate antigen 19-9; MPV, mean platelet volume; PCT, plateletocrit; PDW, platelet distribution width.

• 

  Fig. 3 Kaplan-Meier curves for OS in different subsets of patients with BTC. BTC patients (A), GBC patients (C), ICC patients (E), and ECC patients (G) were stratified by the novel staging system. BTC patients (B), GBC patients (D), ICC patients (F), and ECC patients (H) were stratified according to the AJCC TNM staging system. AJCC, American Joint Committee on Cancer; BTC, biliary tract cancer; GBC, gallbladder cancer; ECC, extrahepatic cholangiocarcinoma; ICC, intrahepatic cholangiocarcinoma; OS, overall survival.

• 

  Fig. 4 Decisive curve analysis of the nomogram. (A) 3-Year survival of the training cohort. (B) 5-Year survival of the training cohort. (C) 3-Year survival of the validation cohort. (D) 5-Year survival of the validating cohort. The horizontal black line denotes no survival, while the gray curve represents all survival.

Reference

References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68:394–424.

2. Macias RI, Kornek M, Rodrigues PM, Paiva NA, Castro RE, Urban S, et al. Diagnostic and prognostic biomarkers in cholangiocarcinoma. Liver Int. 2019; 39(Suppl 1):108–22.

3. Yang P, Javle M, Pang F, Zhao W, Abdel-Wahab R, Chen X, et al. Somatic genetic aberrations in gallbladder cancer: comparison between Chinese and US patients. Hepatobiliary Surg Nutr. 2019; 8:604–14.

4. Squadroni M, Tondulli L, Gatta G, Mosconi S, Beretta G, Labianca R. Cholangiocarcinoma. Crit Rev Oncol Hematol. 2017; 116:11–31.

5. de Aretxabala X. Biliary spillage a new prognostic factor in gallbladder cancer? Hepatobiliary Surg Nutr. 2019; 8:537–8.

6. Valle JW, Lamarca A, Goyal L, Barriuso J, Zhu AX. New horizons for precision medicine in biliary tract cancers. Cancer Discov. 2017; 7:943–62.

7. Kondo N, Murakami Y, Uemura K, Sudo T, Hashimoto Y, Sasaki H, et al. Elevated perioperative serum CA 19-9 levels are independent predictors of poor survival in patients with resectable cholangiocarcinoma. J Surg Oncol. 2014; 110:422–9.

8. Chen M, Lin J, Cao J, Zhu H, Zhang B, Wu A, et al. Development and validation of a nomogram for survival benefit of lymphadenectomy in resected gallbladder cancer. Hepatobiliary Surg Nutr. 2019; 8:480–9.

9. McNamara MG, Templeton AJ, Maganti M, Walter T, Horgan AM, McKeever L, et al. Neutrophil/lymphocyte ratio as a prognostic factor in biliary tract cancer. Eur J Cancer. 2014; 50:1581–9.

10. Stoiber D, Assinger A. Platelet-leukocyte interplay in cancer development and progression. Cells. 2020; 9:855.

11. Zhang K, Gao HF, Mo M, Wu CJ, Hua YQ, Chen Z, et al. A novel scoring system based on hemostatic parameters predicts the prognosis of patients with advanced pancreatic cancer. Pancreatology. 2019; 19:346–51.

12. Gu M, Zhai Z, Huang L, Zheng W, Zhou Y, Zhu R, et al. Pre-treatment mean platelet volume associates with worse clinicopathologic features and prognosis of patients with invasive breast cancer. Breast Cancer. 2016; 23:752–60.

13. Omar M, Tanriverdi O, Cokmert S, Oktay E, Yersal O, Pilanci KN, et al. Role of increased mean platelet volume (MPV) and decreased MPV/platelet count ratio as poor prognostic factors in lung cancer. Clin Respir J. 2018; 12:922–9.

14. Song Q, Wu JZ, Wang S, Chen WH. Elevated preoperative platelet distribution width predicts poor prognosis in esophageal squamous cell carcinoma. Sci Rep. 2019; 9:15234.

15. Chang J, Lin G, Ye M, Tong D, Zhao J, Zhu D, et al. Decreased mean platelet volume predicts poor prognosis in metastatic colorectal cancer patients treated with first-line chemotherapy: results from mCRC biomarker study. BMC Cancer. 2019; 19:15.

16. Haemmerle M, Stone RL, Menter DG, Afshar-Kharghan V, Sood AK. The platelet lifeline to cancer: challenges and opportunities. Cancer Cell. 2018; 33:965–83.

17. Cui MM, Li N, Liu X, Yun ZY, Niu Y, Zhang Y, et al. Platelet distribution width correlates with prognosis of non-small cell lung cancer. Sci Rep. 2017; 7:3456.

18. Li Y, Wu H, Xing C, Hu X, Zhang F, Peng Y, et al. Prognostic evaluation of colorectal cancer using three new comprehensive indexes related to infection, anemia and coagulation derived from peripheral blood. J Cancer. 2020; 11:3834–45.

19. Zhang X, Cui MM, Fu S, Li LL, Liu YS, Liu ZP, et al. Platelet distribution width correlates with prognosis of gastric cancer. Oncotarget. 2017; 8:20213–9.

20. Plantureux L, Mege D, Crescence L, Dignat-George F, Dubois C, Panicot-Dubois L. Impacts of cancer on platelet production, activation and education and mechanisms of cancer-associated thrombosis. Cancers (Basel). 2018; 10:441.

21. Korniluk A, Koper-Lenkiewicz OM, Kaminska J, Kemona H, Dymicka-Piekarska V. Mean platelet volume (MPV): new perspectives for an old marker in the course and prognosis of inflammatory conditions. Mediators Inflamm. 2019; 2019:9213074.

22. Handtke S, Thiele T. Large and small platelets: (when) do they differ? J Thromb Haemost. 2020; 18:1256–67.

23. Jagroop IA, Tsiara S, Mikhailidis DP. Mean platelet volume as an indicator of platelet activation: methodological issues. Platelets. 2003; 14:335–6.

24. Leblanc R, Peyruchaud O. Metastasis: new functional implications of platelets and megakaryocytes. Blood. 2016; 128:24–31.

25. Groot Koerkamp B, Wiggers JK, Gonen M, Doussot A, Allen PJ, Besselink MGH, et al. Survival after resection of perihilar cholangiocarcinoma-development and external validation of a prognostic nomogram. Ann Oncol. 2015; 26:1930–5.

26. Yadav S, Tella SH, Kommalapati A, Mara K, Prasai K, Mady MH, et al. A novel clinically based staging system for gallbladder cancer. J Natl Compr Canc Netw. 2020; 18:151–9.

27. Raoof M, Dumitra S, Ituarte PH, Melstrom L, Warner SG, Fong Y, et al. Development and validation of a prognostic score for intrahepatic cholangiocarcinoma. JAMA Surg. 2017; 152:e170117.

28. Schweitzer N, Fischer M, Kirstein MM, Berhane S, Kottas M, Sinn M, et al. Risk estimation for biliary tract cancer: Development and validation of a prognostic score. Liver Int. 2017; 37:1852–60.

29. Bridgewater J, Lopes A, Wasan H, Malka D, Jensen L, Okusaka T, et al. Prognostic factors for progression-free and overall survival in advanced biliary tract cancer. Ann Oncol. 2016; 27:134–40.

30. Jackson SS, Pfeiffer RM, Liu Z, Anderson LA, Tsai HT, Gadalla SM, et al. Association between aspirin use and biliary tract cancer survival. JAMA Oncol. 2019; 5:1802–4.